C2 Pharma successfully completes validation campaigns for digoxin and digoxin micron
Digoxin is a toxic by-product of foxglove flowers
C2 Pharma has successfully validated its manufacturing process for two APIs: digoxin and digoxin micron. Digoxin is produced at a dedicated manufacturing facility at CMO Laurus Labs, India.
C2 Pharma invested in a state-of-the-art, dedicated production facility for the manufacture of digoxin at the Laurus Labs site in Vizag, India, in May 2017.
The total investment in the facility is close to US $10 million and the facility, which covers an area of more than 1800 m sq, will have an annual production output covering the global demand for digoxin.
“Within 24 months, C2 Pharma and Laurus Labs have been able to complete the construction of the civil works, install and validate the manufacturing equipment, design and validate the manufacturing process and prepare the filing for the regulatory dossier for the two APIs,” said Andrew Badrot, CEO of C2 Pharma.
“This is an astonishing performance and a testament to the partnership that exists between the two companies.”
This investment follows the recent strategic alliance between C2 Pharma and Theracule, which develops orphan drugs for rare neurological disorders, as reported here in Manufacturing Chemist.